MOXATAG (Amoxicillin) 775mg tablets by MiddleBrook Pharmaceuticals Moxatag (amoxicillin extended-release) 775mg tablets will be made available by MiddleBrook Pharmaceuticals in the beginning of March ...

MOXATAG (Amoxicillin) 775mg tablets by MiddleBrook Pharmaceuticals The FDA has approved Moxatag (amoxicillin extended-release tablets, from MiddleBrook) 775mg for the treatment of patients ≥12 years ...

WESTLAKE, Texas--(BUSINESS WIRE)--MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner ...

LONDON (ShareCast) - (ShareCast News) - Pharmaceutical group Vernalis (Stuttgart: BBP2.SG - news) has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand ...

MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and ...

WESTLAKE, Texas MiddleBrook Pharmaceuticals plans to promote its extended-release antibiotic by expanding a Web-based marketing program, the drug maker announced Wednesday. IncreaseRx is a virtual ...

GERMANTOWN, Md., Jan. 24 -- MiddleBrook Pharmaceuticals, a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has received approval ...

The first and only FDA-approved once-daily amoxicillin will be promoted to health care professionals nationwide WESTLAKE, Texas, Jan. 7 /PRNewswire-FirstCall ...

Thank you, Jackie and good morning everyone. Before we begin our call, I would like to remind you that some of the statements made during this call may be considered forward-looking statements. The ...

Vernalis plc ("Vernalis" or the "Company") was informed yesterday that Suir Pharma Limited ("Suir") of Clonmel Ireland, the sole source supplier of finished dosage form Moxatag®, has been placed into ...